Bexsero
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background The UK on 01 September 2015 became the first country to introduce Meningococcal B (Bexsero) vaccine into the national…
The crystal structures and functional characterization of two anti-NHBA human Fabs provide insight into the recognition by human…
Background From September 2015 babies born on or after 1/7/15 are being offered the MenB (meningococcal group B) vaccine, bexsero…
All newborn babies in the UK are now routinely offered the jab against Meningococcal group B (MenB), but there is still work to…
Summary Immunisation against meningococcal meningitis has a long history, which has passed through several phases: the studies by…
The 4-component meningococcal serogroup B vaccine 4CMenB (Bexsero) is the first vaccine against this serogroup and has been…
Background: Meningococcal vaccines in current use contain the capsular polysaccharides of serogroups A, C, Y, and W-135…
Bexsero, a 4 component protein-based meningococcal B vaccine (4CMen B)
manufactured by Novartis was authorised for use by the…